An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-y5exapg2> Pfizer is in a transition phase. Revenues plummeted after the COVID-19 vaccine/treatment boom. Now, with major acquisitions like Seagen and a focus on oncology and non-COVID base business, we model a modest 4% growth rate in cash flow as new drugs offset revenue losses from impending patent expirations (like Eliquis).
" data-astro-cid-y5exapg2> Pfizer is in a transition phase. Revenues plummeted after the COVID-19 vaccine/treatment boom. Now, with major acquisitions like Seagen and a focus on oncology and non-COVID base business, we model a modest 4% growth rate in cash flow as new drugs offset revenue losses from impending patent expirations (like Eliquis).
" data-astro-cid-y5exapg2> Pfizer is in a transition phase. Revenues plummeted after the COVID-19 vaccine/treatment boom. Now, with major acquisitions like Seagen and a focus on oncology and non-COVID base business, we model a modest 4% growth rate in cash flow as new drugs offset revenue losses from impending patent expirations (like Eliquis).
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 7.0% | 7.5% | 8.0% | 8.5% | 9.0% |
|---|---|---|---|---|---|
| 7.0% | $62.60 | $62.60 | $62.60 | $62.60 | $62.60 |
| 7.5% | $62.60 | $62.60 | $62.60 | $62.60 | $62.60 |
| 8.0% | $62.60 | $62.60 | $62.60 | $62.60 | $62.60 |
| 8.5% | $62.60 | $62.60 | $62.60 | $62.60 | $62.60 |
| 9.0% | $62.60 | $62.60 | $62.60 | $62.60 | $62.60 |
■ Undervalued vs current price ■ Overvalued vs current price
Westmount Research. "Pfizer (PFE) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 19, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.